Adrian Burdan

Dr. Adrian Burdan

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2025 in Cancers
Verified
Journal Article
Open access
PDF file
CBCălin Burciu
Călin Burciu
BMBogdan Miutescu
Bogdan Miutescu
RBRenata Bende
Renata Bende
DVDeiana Vuletici
Deiana Vuletici
Tudor Voicu MogaTudor Voicu Moga
Tudor Voicu Moga
Roxana SirliRoxana Sirli
Roxana Sirli
Background/Objectives: Access to healthcare services was significantly restricted during the COVID-19 pandemic, leading to changes in the management of hepatocellular carcinoma (HCC). However, limited research has examined how these changes evolved post-pandemic. This study evaluated the impact of the pandemic at a tertiary center in Romania, focusing on diagnosis rates, treatments, and survival outcomes. Methods: A retrospective study conducted at Timișoara County Hospital divided patients into three equal cohorts of 23 months each: the pre-pandemic period (PreP: 1 May 2018–31 March 2020), the pandemic period (PandP: 1 April 2020–28 February 2022), and the post-pandemic period (PostP: 1 March 2022–31 January 2024). Newly diagnosed HCC cases were evaluated for the tumor stage, biological markers, and treatment received during each period. A survival census was conducted nine months after the diagnosis. Results: During the PandP and PostP periods, the numbers of newly diagnosed HCC cases decreased to 58 cases (p < 0.001) and 64 cases (p < 0.005), respectively, representing reductions of 38.3% and 31.9% compared to the PreP period, which had 94 cases. The proportion of patients in the BCLC-B stage increased from 31.9% in the PreP period to 50% during the PandP period (p = 0.0401), with fewer BCLC-A-0 cases (17% vs 5.1%; p = 0.059) during PandP. The tumor characteristics, BCLC classification, and TNM staging showed no significant differences between the PreP and PostP periods. Systemic therapy was the most commonly used treatment (39.7–50%). No significant differences were observed across treatment types when comparing all three periods (p > 0.05). The median follow-up times in the PreP, PandP, and PostP periods were 157.5, 159.5, and 183.5 days, respectively, with no statistically significant differences. The survival curve showed no statistically significant differences in survival between the groups at the nine-month follow-up (p > 0.05). Conclusions: The COVID-19 pandemic decreased HCC diagnoses, with only a partial rebound in the PostP period that did not reach PreP levels. While the PandP period showed worsening BCLC staging and an increase in tumor numbers, the tumor stage and treatment in the PostP period were similar to those in the PreP period. Similarly, the nine-month survival rates remained similar across all three periods.

15 October 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
BMBogdan Miutescu
Bogdan Miutescu
RBRenata Bende
Renata Bende
FBFelix Bende
Felix Bende
ABAdrian Burdan
Adrian Burdan
Eyad GadourEyad Gadour
Eyad Gadour
IRIulia Maria RATIU
Iulia Maria RATIU
Backg round: Shear-wave elastography (SWE) performed during endoscopic ultrasound (EUS) is a promising tool for quantifying pancreatic stiffness, but its intra-session reproducibility remains incompletely defined. Meth ods: In this prospective single-center study, 86 consecutive patients (median age 66 years; 59.3% women) referred for diagnostic EUS underwent EUS-guided point SWE. Ten measurements were acquired from a 10 × 15 mm region of interest in the pancreatic body or tail when the breath was held by a single expert operator. Reproducibility was assessed by comparing the first and last five acquisitions; intra-individual variability was expressed as the coefficient of variation (CV). Results: Mean stiffness was 18.5 ± 8.9 kPa (2.31 ± 0.58 m/s). Agreement between early and late measurements was excellent in kPa (ICC = 0.99; r = 0.997; mean bias −0.06 kPa) and moderate in m/s (ICC = 0.61; r = 0.61). The mean CVs were 0.640 for kPa and 0.328 for m/s. Sex, age, and BMI had no significant influence on stiffness or reproducibility. The technical success rate was 97%, with no adverse events. Conclusions: EUS-guided point SWE provides highly reproducible pancreatic stiffness measurements within a single session, particularly when expressed in kPa. Demographic factors do not affect stability, supporting its integration into routine EUS practice. Further multicenter studies are needed to establish pathology-specific cut-offs and confirm clinical relevance.

1 March 2026 in Endoscopic Ultrasound
Verified
Journal Article
Open access
BMBogdan Miutescu
Bogdan Miutescu
ABAdrian Burdan
Adrian Burdan
EGEyad Gadour
Eyad Gadour
AFAntonio Facciorusso
Antonio Facciorusso
MAMohammed AlQahtani
Mohammed AlQahtani
APAlina Popescu
Alina Popescu
Background and Objective: EUS point shear‑wave elastography (EUS‑pSWE) permits near‑field, intraluminal assessment of liver stiffness. We examined its concordance with vibration-controlled transient elastography (VCTE) and its diagnostic accuracy for advanced fibrosis (F ≥ 3) in an expanded mixed cohort. Methods: One hundred twenty adults (57% men; mean age: 61 ± 10 years; body mass index: 28.9 ± 4.0) undergoing routine endoscopic ultrasound were prospectively enrolled. VCTE stratified fibrosis as F0–1 (<7.0 kPa, n = 96), F2 (7–9.4 kPa, n = 11) and F3‑4 (≥9.5 kPa, n = 13). In all the patients, 10 EUS‑pSWE measurements were performed in each lobe, and the liver stiffness result was the median value of the 10 measurements. Correlation (Pearson’s r ), Bland–Altman agreement, and diagnostic indices for F ≥3 were calculated. Results: Median EUS‑pSWE increased with fibrosis (left lobe: 5.0 ± 0.9, 7.8 ± 1.0, 15.1 ± 3.4 kPa for F0–1, F2, F3–4; P < 0.001). EUS-pSWE correlated strongly with VCTE ( r = 0.89, left; r = 0.88, right; P < 0.0001). AUROC for detecting F ≥3 reached 0.91 (95% confidence interval: 0.85–0.96) for the left and 0.89 (0.83–0.95) for the right lobe. A 10.2 kPa cutoff value for F3 afforded 85% sensitivity, 84% specificity, positive predictive value 72%, and negative predictive value 93%. EUS-pSWE provided lobe-independent stiffness estimates that tracked VCTE closely to recognize advanced fibrosis. Conclusions: Its high diagnostic accuracy across fibrosis stages and ability to integrate seamlessly into routine EUS make EUS-pSWE a valuable tool for comprehensive liver assessment.

17 April 2026 in Medicina
Verified
Journal Article
Open access
PDF file
ABAdrian Burdan
Adrian Burdan
BMBogdan Miutescu
Bogdan Miutescu
Eyad GadourEyad Gadour
Eyad Gadour
CBCălin Burciu
Călin Burciu
MDMirela Danila
Mirela Danila
Alina PopescuAlina Popescu
Alina Popescu
Background and Objectives: Endoscopic ultrasound point shear-wave elastography (EUS-pSWE) bypasses subcutaneous fat and may provide weight-independent liver stiffness measurements; however, data on reproducibility and quality criteria remain limited. This study aimed to evaluate the intra-observer reproducibility and short-term variability of EUS-pSWE. Materials and Methods: In this single-center prospective cohort study (December 2024–February 2025), 120 consecutive adults undergoing diagnostic EUS were enrolled. For each hepatic lobe, 10 consecutive measurements were obtained and grouped into two sequential blocks of five measurements without scope repositioning. Intra-observer reproducibility was assessed using intraclass correlation coefficients (ICC3,1). The agreement between acquisition runs and determinants of short-term variability was also evaluated. Same-day vibration-controlled transient elastography (VCTE) served as an external comparator. Results: Forty-six participants were obese (BMI ≥ 30 kg/m2). The mean VCTE stiffness was 6.24 kPa, while the mean EUS-pSWE stiffness was 9.40 ± 5.64 kPa. Among examinations meeting IQR/Median < 30% quality criteria, reproducibility was excellent (left ICC 0.97 [0.95–0.98]; right ICC 0.92 [0.86–0.95]) and consistent across BMI strata. EUS-pSWE correlated strongly with VCTE (r = 0.81, p < 0.001). In contrast, agreement between consecutive acquisition runs was low, indicating increased short-term variability. EUS-pSWE quality pass rates based on IQR/Median criteria were modest (left 56.7%, right 41.7%, both lobes 23.3%), although all measurements fulfilled device-specific validity criteria (VSN > 60%). Age and BMI were not significant predictors of variability. Conclusions: EUS-pSWE demonstrates excellent intra-observer reproducibility under quality-controlled conditions and shows a strong correlation with VCTE. However, short-term variability between acquisition runs and limited feasibility based on conventional quality thresholds should be considered. EUS-pSWE appears to be a promising modality for liver stiffness assessment, warranting further validation of quality criteria and clinical thresholds.